Rabbit anti-Human PD-L1 Monoclonal Antibody | anti-PD-L1 antibody

PD-L1

Cat. Num. AAA344033

• Gene Names: CD274; B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
• Reactivity: Human
• Synonyms: PD-L1; Monoclonal Antibody; anti-PD-L1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Monoclonal
• Form/Format: Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
• Sequence Length: 245

• Application Notes: The recommended working dilution range is 1:100 - 1:200.
• Positive Control: Tonsil, Lung Adenocarcinoma
• Principles and Procedures: Visualization of the antigen present in tissue sections is accomplished in a multi-step immunohistochemical staining process, in conjunction with a horseradish peroxidase (HRP) or alkaline phosphatase (AP) linked detection system. The process involves the addition of the stated antibody (primary antibody) to a tissue slide, followed by a secondary antibody (linked to an enzyme complex) which specifically binds to the primary antibody. A chromogenic substrate is then added which reacts with the enzyme complex, resulting in a colorimetric reaction at the site of the antigen. Results are interpreted using a light microscope.
• Reconstitution: The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining.; The concentrated antibody requires dilution in the optimized buffer, to the recommended working dilution range.
• Specimen Collection and Preparation for Analysis: Each tissue section should be fixed with 10% neutral buffered formalin, cut to the applicable thickness (4um), and placed on a glass slide that is positively charged. The prepared slide may then be baked for a minimum of 30 minutes in a 53-65 degree C oven (do not exceed 24 hours).; Note: Performance evaluation has been shown on human tissues only. Variable results may occur due to extended fixation time or special processes of specific tissue preparations.
• Preparation and Storage: Store at 2-8 degree C. Do not freeze.; To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position.; Positive and negative controls should be simultaneously run with unknown specimens.

Immunohistochemistry (IHC)

(PD-L1 [IHC411] on Lung)

Related Product Information for anti-PD-L1 antibody

Intended Use: The PD-L1 [IHC411] antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods.
Description: Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.

References

1. Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.
2. Tokito T, et al. Eur J Cancer. 2016; 55:7-14.
3. Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.
4. Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.
5. Xia B, et al. Immunotherapy. 2016; 8:279-98.
6. Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.
7. Singh BP, et al. Cancers (Basel). 2016; 8.
8. Chemnitz JM, et al. J Immunol. 2004; 173:945-54.
9. Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174-9.
10. Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.
11. Mozaffarian N, et al. Rheumatology, 2008; 47:1335-41.

NCBI and Uniprot Product Information

• NCBI GI #: 930425329
• NCBI GeneID: 29126
• NCBI Accession #: NP_001300958.1
• NCBI GenBank Nucleotide #: NM_001314029.1
• Molecular Weight: 20,246 Da
• NCBI Official Full Name: programmed cell death 1 ligand 1 isoform c
• NCBI Official Synonym Full Names: CD274 molecule
• NCBI Official Symbol: CD274
• NCBI Official Synonym Symbols: B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
• NCBI Protein Information: programmed cell death 1 ligand 1
• UniProt Protein Name: Programmed cell death 1 ligand 1
• UniProt Gene Name: CD274
• UniProt Synonym Gene Names: PD-L12 PublicationsManual assertion based on opinion iniRef.10; PDCD1 ligand 1; Programmed death ligand 1; B7-H11 PublicationManual assertion based on opinion iniRef.1

NCBI Description

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Uniprot Description

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).